Pharmaceutical

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision…

8 months ago

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing…

8 months ago

Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

8 months ago

Evotec welcomes Aurélie Dalbiez as Chief People Officer

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced…

8 months ago

Glaukos Announces the Release of its 2023 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the…

8 months ago

PharmAlliance Announces Acquisition of CHEORS

MORRISVILLE, N.C.--(BUSINESS WIRE)--#acquisition--PharmAlliance, a diversified pharmaceutical and life sciences services platform, is pleased to announce the acquisition of Complete Health…

8 months ago

Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

TYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and…

8 months ago

Scientific Industries Announces Appointment of Industry Leader Michael Blechman as New Board Member

BOHEMIA, NY / ACCESSWIRE / April 16, 2024 / Scientific Industries, Inc. (OTCQB:SCND) ("SI") announced the appointment of Michael Blechman…

8 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription productOral mucositis, also called "chemo…

8 months ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertiseCollaboration aims to…

8 months ago